The Form 4 filing, a report of changes in an insider's share ownership, was submitted on November 2, 2026. All five sales took place that same day.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-02 |
| Date of Latest Transaction | 2026-11-02 |
| Buy/Sell | sell |
| Transaction Count | 5 |
| Shares Transacted | 25,000 |
| Price | $95.60 |
| Total Transaction Value | $2,390,124.91 |
| Insider | |
| Ticker Symbol | ORKA |
| Company | Oruka Therapeutics, Inc. |
| Insider Name | Klein Lawrence Otto |
| Insider Title | Chief Executive Officer |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 923,128 |
| Position Size Change | 2.64% |
| Filing | |
| Filing Date | 2026-11-02 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported under SEC transaction code S. The five transactions involved Lawrence Otto Klein, chief executive officer of Oruka Therapeutics (ORKA).
What was the average price of the transaction?
The average price was $95.60 per share, rounded to the nearest cent. Separate prices for each of the five sales are not available here.
How did this transaction affect the insider's holdings?
Lawrence Otto Klein sold 25,000 shares and reported 923,128 shares owned afterward. The shares sold made up 2.64% of the shares held before the sales.
What's the total transaction value?
The five sales had a total value of $2,390,124.91, rounded to the nearest cent. That total covers all 25,000 shares sold.
Are there any special circumstances around this transaction?
The transaction information notes a Rule 10b5-1 trading-plan reference. These plans set trading instructions in advance. The reference may apply to the filing as a whole. Footnote text is not available here, so it is unclear which of the five sales it covers. The plan's start date and trading terms are also unknown.
For research purposes only; not investment advice.